百利天恒：T-Bren(HER2 ADC)用于HER2阳性局部晚期或转移性胃或胃食管结合部腺癌患者纳入突破性治疗品种名单

Core Viewpoint - The company, Bai Li Tian Heng (688506.SH), has announced that its self-developed innovative biopharmaceutical T-Bren (HER2 ADC) has shown significant anti-tumor efficacy in clinical trials and has been included in the list of breakthrough therapies by the National Medical Products Administration for patients with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma who have failed prior treatments [1] Group 1 - T-Bren (HER2 ADC) is a targeted innovative ADC with best-in-class potential [1] - The drug has demonstrated significant anti-tumor efficacy in clinical trials [1] - It is specifically for patients who have failed first-line anti-HER2 treatment and standard chemotherapy [1] Group 2 - The National Medical Products Administration has included T-Bren in its list of breakthrough therapies [1] - The announcement indicates a positive regulatory recognition for the drug's potential [1] - The completion of the public announcement signifies a step forward in the drug's development process [1]